

ESTRADIOL ASSAY – CROSS REACTIVITY WITH FULVESTRANT Lab Bulletin for Oncology Practices

Effective Date: March 4, 2016

We have been informed by Siemens that the estradiol assay used at Beaumont Laboratory is subject to interference by the drug Fulvestrant.

Fulvestrant is used in post-menopausal women being treated for estrogen receptor positive recurrent stage IV breast cancer. If estradiol is measured on a patient being treated with Fulvestrant, the estradiol will be falsely elevated, possibly into a premenopausal range.

If estradiol testing is required on such a patient, please order **Estrogens, serum fractionated**. The sample will then be sent to Mayo Medical Labs for testing by LC-MS.

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Internal URL to Laboratory Bulletins:

http://employee.beaumont.edu/portal/pls/portal/ip30dev.page_pkg.page?xid=lab_bulletins

External URL to Laboratory Bulletins:

<http://beaumontlaboratory.com/hospitals-laboratories-three/test-information-center/laboratory-bulletins/>

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>.

Date submitted: March 3, 2016

Submitted by: Elizabeth Sykes, M.D., Medical Director, Automated Chemistry & Special Testing, Royal Oak
Yvonne Posey, M.D., Medical Director, Send Out Lab, Royal Oak
Kenneth Simkowski, Sr., Ph.D., Technical Director Chemistry, Royal Oak

Beaumont Laboratory
Customer Service
1-800-551-0488